BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease ...

MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical ...

BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting - - IND clearance expands Company's advanced clinical pipeline for ...

The pain can range from cervical intervertebral discs, facet joints to atlantoaxial joints. Cervical discogenic pain syndrome is a common source of neck pain with a reported prevalence between 16% to ...

MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) ...

The company is planning a Phase 2 study for BRTX-100, indicating progress in clinical development and commitment to addressing chronic cervical discogenic pain, which affects a large segment of ...

In the meantime, we continue to advance our FDA Fast Track-designated BRTX-100 chronic lumbar disc disease (cLDD) program.” 1 Saini A, Mukhdomi T. Cervical Discogenic Syndrome. 2023 Apr 3. In: ...

BioRestorative Therapies (BRTX) announced the U.S. Food and Drug Administration has cleared its Investigational New Drug application for ...

Many patients with lower back pain, sciatica, pain down the back of the legs, or weakness of the lower-extremity muscles are diagnosed with a herniated (a.k.a. compressed or ruptured) spinal disc.